FELIX post-hoc data reinforce obe-cel durability
A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile
EHA 2025
News
Leukemia
Young Investigator Program
Dr. Gonzalez Lugo reflects on the SOHO YIP award
Meet Jesus Gonzalez Lugo, MD, an assistant professor of medicine at the University of Kansas and a 2024 SOHO Young Investigator Program (YIP)
Leukemia
Acute Myeloid Leukemia
New immunotherapy approach may treat aggressive AML, MDS
Researchers conducted a proof-of-concept study for genetically redirecting T cells, offering a potential immunotherapy target for acute myeloid leukemia (AML) and myelodysplastic syndromes
ASCO 2025
Isatuximab with KRd boosts sustained MRD negativity in myeloma
Patients with newly-diagnosed multiple myeloma (MM) treated with isatuximab plus carfilzomib, lenalidomide, dexamethasone (IsaKRD) in induction, consolidation, and light consolidation phases saw sustained measurable
ASCO 2025
Sintilimab plus ICE regimen significantly improves complete remission in classical Hodgkin lymphoma
Sintilimab plus ifosfamide, carboplatin, and etoposide (ICE) as second-line treatment of classical Hodgkin lymphoma (cHL) significantly improved complete remission rates (CRRs) compared with
Leukemia
Chronic Myeloid Leukemia
Generic version of nilotinib enters US market for treatment of certain leukemias
A generic version of nilotinib (Tasigna®) entered the US market on May 27, 2025, with 180 days of exclusivity, reported Apotex, the pharmaceutical
ASCO 2025
Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML
The phase 3 QuANTUM-Wild study is assessing the use of quizartinib plus standard induction/consolidation chemotherapy and maintenance therapy in newly-diagnosed patients with FLT3-ITD-negative acute
ASCO 2025
Meetings / Conferences
Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma
A phase 3 study is assessing a measurable residual disease (MRD)-driven consolidation and maintenance strategy for patients with newly diagnosed multiple myeloma (NDMM).
Leukemia
Chronic Myeloid Leukemia
News
Making resistance futile: lessons from the fields
In this editorial, SOHO Insider Associate Editor Dr. Jerry Radich draws a parallel between cancer treatment and agricultural pest control.
Cellular Therapy
Lymphoma
Armored CAR-T option shows promise in previously CAR-treated lymphoma
A small phase 1 study published in The New England Journal of Medicine found that the investigational anti-CD19 armored chimeric antigen receptor (CAR)